Buprenorphine is one of three drugs approved by the US Food and Drug Administration for long-term treatment of opioid use disorder, and it is widely regarded as among the most effective and accessible options. The medication works by reducing cravings and easing withdrawal symptoms, which in turn lowers the risk of overdose. It occupies opioid receptors in the brain in a way that blunts the euphoric effects of other opioids while preventing the physical agony of withdrawal, allowing patients to stabilize their lives and remain engaged in care. Unlike some other treatments, buprenorphine can now be prescribed in doctor’s offices and pharmacies, following a December 2025 law intended to expand access, a shift that matters enormously as fentanyl, which is up to 50 times stronger than heroin, continues to drive the opioid overdose epidemic across the United States.

Pregnancy, however, fundamentally changes how the body handles this medication. Physical and hormonal changes accelerate the metabolization of buprenorphine in pregnant patients, meaning that higher doses are often required for them to avoid withdrawal. This is not a marginal effect: data suggest that up to 90 percent of pregnant women with opioid use disorder require higher doses of the drug. The problem is compounded by the fentanyl era, since increased doses are often necessary even for people who are not pregnant to adequately counteract the potency of illicit synthetic opioids. A typical daily dose of buprenorphine administered under the tongue begins at 2 to 4 milligrams, with the standard target dosage reaching 16 to 24 milligrams, though some patients can benefit from doses up to 32 milligrams.

Despite a growing body of research supporting increased dosages as clinically needed, buprenorphine treatment during pregnancy remains inconsistent, and patients frequently receive inadequate amounts of the medication. Clinical guidelines on dosing for pregnant and postpartum patients are vague and offer little direction on dose adjustment. State Medicaid policies often go further still, capping doses in ways that are not grounded in the evidence. In some states, pregnancy guidance around buprenorphine includes language that implies dose minimization should be the goal, an approach that contradicts decades of evidence about the clinical needs of pregnant patients with opioid use disorder.

Dr. Morgan, a research assistant professor of health law, policy and management at Boston University School of Public Health, has built his career around the opioid overdose epidemic and the question of how to improve access to and retention on medications for opioid use disorder. He argues that the gap between what the evidence shows and what policy allows is both wide and consequential. Pregnant women generally metabolize drugs differently than non-pregnant individuals due to the profound physiological changes of gestation, and the failure to adjust dosing accordingly can push patients into withdrawal, a condition that carries serious risks for both mother and fetus and that frequently drives people back to illicit opioid use.

Dr. Leech, an assistant professor of health policy at Vanderbilt University School of Medicine, points to a phenomenon known as therapeutic inertia as a key driver of dangerous underdosing. In pregnancy, clinical uncertainty and concerns about fetal safety can make clinicians reluctant to increase medication doses even when the evidence supports doing so. The result is a system in which pregnant patients may be left under-treated at precisely the moment when stable, sustained treatment matters most, both for their own health and for the health of their babies. Her work focuses on how coverage decisions and policy design shape real-world treatment patterns and outcomes.

The new study will concentrate on pregnant women covered by Medicaid, a population that is central to this public health challenge. State Medicaid programs cover more than 80 percent of pregnant women with opioid use disorder in the United States, which makes Medicaid dosing policies a decisive lever in whether these patients receive adequate care. Yet many Medicaid programs cap daily dosages of buprenorphine, and some states actively discourage physicians from increasing the dosage during a patient’s pregnancy. The researchers will collaborate with investigators from Boston Medical Center to assess national and state-level differences in buprenorphine dosing between pregnant and non-pregnant women with opioid use disorder, examining how dosing patterns have evolved over time and in response to the spread of fentanyl.

Beyond documenting these patterns, the team will examine the effectiveness of different buprenorphine dosage thresholds and how those dosages advance or inhibit sustained treatment. Retention in treatment is one of the most important predictors of outcomes in opioid use disorder, since patients who discontinue medication face sharply elevated risks of relapse and overdose. Understanding whether higher doses keep pregnant patients engaged in care longer, and whether inadequate doses push them toward treatment discontinuation, could reshape clinical practice and coverage policy alike. The researchers will also estimate the long-term health and economic consequences of suboptimal dosing by applying a decision analytic model capable of projecting multiple outcomes among pregnant and postpartum women with opioid use disorder, including treatment discontinuation, postpartum treatment continuation, overdose, infant outcomes, life expectancy, and healthcare utilization, as well as the cost-effectiveness of restricting or increasing Medicaid dosing limits.

Decision analytic modeling occupies a distinctive niche in health services research because it allows investigators to quantify outcomes that would be infeasible or unethical to assess in clinical trials. As Dr. Leech explains, the approach can leverage existing evidence on dosing effects to project outcomes such as maternal and infant lives lost and the long-term costs of untreated opioid use disorder or suboptimal care, providing a rigorous method for comparing the tradeoffs of different coverage decisions. Rather than waiting years for observational data to accumulate, policymakers could use these projections to weigh the consequences of dose caps against the benefits of more generous dosing thresholds, with estimates spanning both health effects and budget impacts.

For the research team, the ultimate ambition is to translate a technical dosing question into a policy and ethical imperative. By demonstrating that higher buprenorphine dosing during pregnancy improves maternal and infant outcomes and is cost-effective, Dr. Morgan and Dr. Leech hope to give state Medicaid programs and clinical guideline writers the evidence they need to abandon dose minimization policies and embrace dosing strategies grounded in the realities of pregnancy metabolism and the fentanyl-dominated drug supply. If successful, the five-year project could help ensure that one of the most effective tools against the opioid epidemic finally works as well for pregnant women as it does for everyone else, turning a preventable source of maternal and infant harm into an opportunity for meaningful public health gains.

Subject of Research: Effectiveness and health-economic consequences of higher-dosage buprenorphine treatment for pregnant women with opioid use disorder

Article Title: Professors receive $3.7 million NIH grant to study effectiveness of higher-dosage buprenorphine among pregnant women with opioid use disorder

Article References: Professors receive $3.7 million NIH grant to study effectiveness of higher-dosage buprenorphine among pregnant women with opioid use disorder. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: buprenorphine, opioid use disorder, pregnancy, Medicaid, NIH grant, maternal health, fentanyl, health policy, decision analytic modeling, overdose prevention, Boston University, Vanderbilt University

The selection process itself signals how far Kirabo’s ideas have traveled. Recipients are chosen by the editors-in-chief of the American Heart Association’s 14 peer-reviewed scientific journals, and the award explicitly celebrates research that transforms or changes the direction of cardiovascular science. In Kirabo’s case, the transformation is easy to trace. For decades, hypertension was understood primarily as a disorder of blood vessels, kidneys, and the nervous system — a plumbing problem of constricted arteries and sodium retention. Her research demonstrated that the immune system is not a bystander in this process but an active participant, with immune cell activation and inflammatory signaling capable of driving vascular dysfunction and elevating blood pressure. That reframing has reshaped how investigators around the world approach the mechanisms of hypertension and, increasingly, how they search for new drugs against it.

The technical core of Kirabo’s most influential work lies in the chemistry of lipid oxidation. When fats in the body undergo oxidation, they generate highly reactive molecules that can chemically modify proteins, forming what are known as lipid oxidation-derived protein adducts. Kirabo’s laboratory showed that these altered proteins act as neoantigens — molecular patterns that the immune system can recognize as foreign even though they arise from the body’s own tissues. When antigen-presenting cells encounter these neoantigens, they become activated and in turn stimulate T-cell responses. Those T cells, a central arm of adaptive immunity, then contribute to vascular dysfunction, promoting the endothelial impairment and inflammatory milieu that ultimately raise blood pressure. The discovery provided a mechanistic bridge between oxidative stress, a long-recognized feature of hypertension, and the immune activation that accompanies it, fundamentally changing scientific understanding of how the immune system contributes to blood pressure regulation.

That bridge has proven to be a productive place to build. Kirabo’s subsequent work has identified potential therapeutic targets arising directly from this immune-centered model of hypertension, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways operating in immune cells. Isolevuglandins are among the most reactive products of lipid peroxidation, capable of cross-linking and irreversibly modifying proteins, and their accumulation has been implicated in the formation of the very protein adducts that trigger immune recognition. Sodium-sensing pathways in immune cells, meanwhile, suggest a mechanism by which dietary salt — the classic environmental driver of hypertension — might act directly on immune cells to promote their activation, linking a nutritional exposure to an immunological response. Together, these lines of investigation have opened possibilities for preventing and treating hypertension and related cardiovascular and kidney diseases that extend well beyond conventional approaches centered on diuretics, vasodilators, and blockers of the renin-angiotensin system.

Manesh R. Patel, M.D., FAHA, the American Heart Association’s 2026-2027 volunteer president and the Richard S. Stack, M.D. Distinguished Professor of Medicine at Duke University, framed the significance of the work in announcing the award. “Dr. Annet Kirabo exemplifies the spirit of the Joseph A. Vita Award, which recognizes research that changes the direction of cardiovascular science,” Patel said. “Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease. Through innovative, multidisciplinary research, she has uncovered potential therapeutic targets, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways in immune cells, that have opened exciting possibilities for preventing and treating hypertension and related cardiovascular and kidney diseases.”

The scope of Kirabo’s research program reflects the multidisciplinary approach that Patel described. Her laboratory today combines immunology, vascular biology, genomics, metabolomics, and single-cell technologies to identify new therapeutic strategies for cardiovascular and kidney disease. Single-cell approaches, in particular, have become a powerful tool in immunology, allowing researchers to resolve the heterogeneity of immune cell populations that bulk measurements average away — a capability well suited to dissecting which subsets of T cells and antigen-presenting cells participate in hypertensive vascular injury. Metabolomics and lipidomics, for their part, allow the reactive lipid species at the heart of her model to be catalogued and quantified, connecting the chemistry of oxidation to the cellular biology of inflammation. Her research spans the full spectrum of discovery science, from defining fundamental disease mechanisms to advancing translational research with the potential to transform patient care.

The scientific output behind the award is substantial. Kirabo has authored more than 230 scientific publications, sustained funding from the National Institutes of Health, and published numerous influential articles in the American Heart Association’s journals — a criterion directly relevant to an award named for the founding editor of one of them. Her work has established new directions in cardiovascular science and continues to influence investigators worldwide, particularly those studying the intersection of inflammation, oxidative stress, and vascular disease. The immune hypothesis of hypertension that her findings helped establish is now a recognized framework within the field, informing studies of hypertensive end-organ damage in the kidney, heart, and brain as well as the vasculature itself.

Kirabo’s relationship with the American Heart Association extends well beyond this year’s award. She has been an active volunteer with the organization since 2009, serving on the Council on Hypertension Communications Committee since 2018, including as its chair from 2022 to 2024, and on the Council Operations Committee since 2024. She has reviewed Association research proposals since 2017 and chaired sessions at scientific meetings in 2018, 2022, and 2023. Her editorial service includes membership on the editorial board of the journal Hypertension since 2018 and an associate editorship at Circulation Research since 2019 — roles that place her at the gatekeeping junction of the same journals whose editors selected her for the Vita Award.

Her scientific trajectory is itself a story of international training and reinvention. Kirabo earned her doctor of veterinary medicine degree with honors from Makerere University in Uganda before completing a master of science in cell and molecular biology at St. Cloud State University in Minnesota and a doctorate in physiology and functional genomics at the University of Florida in Gainesville. She then completed postdoctoral training in cardiovascular disease and inflammation at Vanderbilt University, where she now leads an internationally recognized research program. In her own words, the recognition carries personal weight. “I am deeply honored to receive the Joseph A. Vita Award from the American Heart Association, an organization that has supported my career from my predoctoral and postdoctoral fellowships through my development as an independent investigator,” Kirabo said. “Scientific discovery, mentorship and advancing new treatments for cardiovascular disease have been the primary focus of my career, and it is both rewarding and humbling to be recognized for it.”

Beyond her laboratory’s discoveries, Kirabo’s influence on the field runs through the scientists she has trained. A dedicated mentor and educator, she has trained dozens of graduate students, postdoctoral fellows, and early-career investigators, many of whom have gone on to faculty positions and independent research careers of their own. Her commitment to mentorship, scientific collaboration, and innovation continues to shape the future of cardiovascular research while expanding opportunities for emerging scientists around the world. As hypertension remains the leading modifiable risk factor for premature death globally, the recognition of work that reframed the disease as an immunological as well as a hemodynamic disorder underscores a broader lesson in biomedical science: the most transformative discoveries often come from looking at a familiar problem through an entirely different disciplinary lens.

Subject of Research: The role of immune activation and inflammation in hypertension, recognized by the 2026 Joseph A. Vita Award

Article Title: Scientist whose work revealed immune system-hypertension link to receive the 2026 Joseph A. Vita Award

Article References: Scientist whose work revealed immune system-hypertension link to receive the 2026 Joseph A. Vita Award. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hypertension, immunology, inflammation, isolevuglandins, T cells, neoantigens, lipid oxidation, vascular biology, American Heart Association, Joseph A. Vita Award, Vanderbilt University, cardiovascular disease